000			01834 a2200529 4500
005			20250516202416.0
264		0	_c20150112
008			201501s 0 0 eng d
022			_a1791-2431
024	7		_a10.3892/or.2014.3070 _2doi
040			_aNLM _beng _cNLM
100	1		_aGeisler, K
245	0	0	_aNilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. _h[electronic resource]
260			_bOncology reports _cMay 2014
300			_a2015-20 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aB-Lymphocytes _ximmunology
650	0	4	_aBenzamides _xtherapeutic use
650	0	4	_aDNA-Binding Proteins _xgenetics
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aImatinib Mesylate
650	0	4	_aInterferon-gamma _xbiosynthesis
650	0	4	_aInterleukin-2 _xtherapeutic use
650	0	4	_aKiller Cells, Natural _ximmunology
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMelanoma, Experimental _xdrug therapy
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Knockout
650	0	4	_aPiperazines _xtherapeutic use
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aT-Lymphocytes _ximmunology
650	0	4	_aTumor Necrosis Factor Receptor Superfamily, Member 7 _xbiosynthesis
700	1		_aReischer, A
700	1		_aKroeger, I
700	1		_aJacobs, B
700	1		_aMeinhardt, K
700	1		_aBauer, R
700	1		_aRyffel, B
700	1		_aMackensen, A
700	1		_aUllrich, E
773	0		_tOncology reports _gvol. 31 _gno. 5 _gp. 2015-20
856	4	0	_uhttps://doi.org/10.3892/or.2014.3070 _zAvailable from publisher's website
999			_c23637787 _d23637787